Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Genetic Diseases, Inborn 1Anemia, Refractory, with Excess of Blasts 1Anemia, Aplastic 1

Interventions

Rituximab 5fludarabine 4Cyclophosphamide 4pembrolizumab 2Bendamustine Hydrochloride 268Ga-pentixafor 2venetoclax 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1motexafin gadolinium 1ibrutinib 1fludarabine phosphate 1daratumumab 1brexucabtagene autoleucel 1acalabrutinib 1Vincristine 1Valproic Acid 1Transplantation 1Tablets 1Surveys and Questionnaires 1Sugars 1Stem Cell Transplantation 1Simvastatin 1Roflumilast 1Ribavirin 1Radiotherapy 1Procarbazine 1Positron-Emission Tomography 1Pemetrexed 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma × Transplantation × Clear all
NCT00212407 2018-11-02

New York Blood Center National Cord Blood Program

New York Blood Center

Phase EARLY_PHASE1 Terminated
4,476 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡